share_log

BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study

BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study

簡介-經皮冠狀動脈介入治療研究的最新藥物
reuters ·  2021/11/04 18:16

Nov 4 (Reuters) - Medicure Inc MPH.V :

路透11月4日電-Medicure Inc MPH.V:

* MEDICURE ANNOUNCES THAT THE SHORTENED AGGRASTAT® VERSUS INTEGRILIN® IN PERCUTANEOUS CORONARY INTERVENTION (SAVI-PCI) STUDY HAS MET ITS PRIMARY ENDPOINT

*Medure宣佈,縮短的Aggrastat®與Integrlin®In Perkins冠狀動脈介入(SAVI-PCI)研究已達到其主要終點

Source text for Eikon: ID:nCNW6qSwXa Further company coverage: MPH.V

Eikon的源文本:ID:nCNW6qSwXa進一步的公司報道:MPH.V

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論